Investment analysts at Oppenheimer Holdings Inc. began coverage on shares of Aduro Biotech, Inc. (NASDAQ:ADRO) in a research note issued to investors on Monday. The firm set a “buy” rating and a $15.00 price target on the biotechnology company’s stock. Oppenheimer Holdings Inc.’s price objective points to a potential upside of 81.82% from the company’s previous close.

Several other brokerages have also recently issued reports on ADRO. HC Wainwright set a $18.00 price target on Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research cut Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub cut Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on Aduro Biotech and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Cowen and Company initiated coverage on Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.14.

Aduro Biotech (NASDAQ:ADRO) traded down 0.60% during mid-day trading on Monday, reaching $8.25. The company’s stock had a trading volume of 453,521 shares. The firm has a 50 day moving average price of $10.25 and a 200-day moving average price of $10.84. Aduro Biotech has a 1-year low of $8.05 and a 1-year high of $15.52. The company’s market capitalization is $615.55 million.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The firm had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. During the same quarter last year, the business posted $0.03 earnings per share. The firm’s revenue for the quarter was down 84.9% compared to the same quarter last year. On average, equities analysts predict that Aduro Biotech will post ($1.35) EPS for the current fiscal year.

WARNING: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/30/oppenheimer-holdings-inc-begins-coverage-on-aduro-biotech-inc-adro.html.

In related news, insider Thomas W. Dubensky sold 50,000 shares of Aduro Biotech stock in a transaction on Friday, August 11th. The stock was sold at an average price of $11.38, for a total value of $569,000.00. Following the transaction, the insider now directly owns 80,812 shares in the company, valued at approximately $919,640.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dirk G. Brockstedt sold 10,000 shares of Aduro Biotech stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.59, for a total value of $105,900.00. The disclosure for this sale can be found here. Insiders sold a total of 342,745 shares of company stock worth $3,956,397 over the last 90 days. Insiders own 6.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc grew its holdings in shares of Aduro Biotech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 1,043 shares during the last quarter. American International Group Inc. grew its holdings in shares of Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 1,447 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 2,119 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 2,515 shares during the last quarter. Finally, Nationwide Fund Advisors grew its holdings in shares of Aduro Biotech by 12.5% in the 2nd quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 2,567 shares during the last quarter. Institutional investors and hedge funds own 35.24% of the company’s stock.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.